Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 20;5(1):147-152.
doi: 10.1002/jha2.835. eCollection 2024 Feb.

Immune reconstitution inflammatory syndrome-associated lymphoma: A retrospective Brazilian cohort

Juliano Cordova Vargas  1   2   3 , Karin Zattar Cecyn  1 , Mariana de Oliveira Marques  1   4 , Juliana Pereira  5 , Walter M Tobias Braga  6 , Nelson Hamerschlak  2   7 , Jacques Tabacof  8 , Caina D de Liz  9 , André Abdo  4 , Paulo Roberto Abrão Ferreira  10 , Gisele W Braga Colleoni  1 , Otavio C G Baiocchi  1   4
Affiliations

Immune reconstitution inflammatory syndrome-associated lymphoma: A retrospective Brazilian cohort

Juliano Cordova Vargas et al. EJHaem. .

Abstract

After initiating combined antiretroviral therapy (cART), individuals with human immunodeficiency virus (HIV) may develop Hodgkin/non-Hodgkin lymphoma due to immune reconstitution inflammatory syndrome (IRIS). This retrospective cohort study evaluated the incidence, clinical features and prognosis of IRIS-associated lymphomas in Brazilian patients. Incidence in 2000-2019 was 9.8% (27/276 patients with HIV and lymphoma; viral load drop >1 log). Time between HIV diagnosis and cART initiation was <1 year in 70.3% of cases. Time between cART initiation and lymphoma diagnosis was <3 months in 11 cases and 3-6 months in 16 cases. Overall and progression-free survival rates were similar between cases of non-IRIS-associated lymphoma and IRIS-associated lymphoma.

Keywords: antiretroviral therapy; immune reconstitution inflammatory syndrome; lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
(A) Progression‐free survival; (B) overall survival; (C) progression‐free survival probability analysis comparing patients with immune reconstitution inflammatory syndrome (IRIS)‐associated lymphoma (grey line) and those with non‐IRIS‐associated lymphoma (black line); (D) overall survival probability analysis comparing patients with IRIS‐associated lymphoma (grey line) and those with non‐IRIS‐associated lymphoma (black line).
See this image and copyright information in PMC

References

    1. Noy A. Optimizing treatment of HIV‐associated lymphoma. Blood. 2019;134:1385–1394. - PMC - PubMed
    1. Brazilian Ministry of Health . Protocolo clínico e diretrizes terapêuticas para manejo da infecção pelo HIV em adultos [Clinical Protocol and therapeutic guidelines for the management of HIV infection in adults]. Brasília: Ministério da Saúde, Secretaria de Vigilância em Saúde; 2018.
    1. Gopal S, Patel MR, Achenbach CJ, Yanik EL, Cole SR, Napravnik S, et al. Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. Clin Infect Dis. 2014;59:279–286. - PMC - PubMed
    1. Vargas JC, Marques MO, Pereira J, Braga WMT, Hamerschlak N, Tabacof J, et al. Factors associated with survival in patients with lymphoma and HIV: the largest cohort study in Brazil. AIDS. 2023;37(8):1217–1226. 10.1097/QAD.0000000000003549 - DOI - PubMed
    1. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. International Network for the Study of HIV‐associated IRIS. Tuberculosis‐associated immune reconstitution inflammatory syndrome: case definitions for use in resource‐limited settings. Lancet Infect Dis. 2008;8:516–523. - PMC - PubMed